The invention pertains to fused cyclic compounds having the formula, ##STR1##

wherein G is an optionally substituted aryl or heterocyclo, L is an optional linker, M is a bond, O, CR⁷R⁷ or NR¹⁰, and M is a bond or NR¹⁰, with the proviso that at least one of M or M must be a bond; E is CZ₂, CR⁷CR⁷, SO₂, POR², or POOR²; Z₁ is O, S, NH, or NR⁶; Z₂ is O, S, NH, or NR⁶; A₁ is CR⁷ or N; A₂ is CR⁷ or N; Y is J—J—J" where J is (CR⁷R⁷)n and n=0-3, J is a bond or O, S, SO, SO₂, NH, NR⁶, CO, OCO, NR¹CO, CR⁷R⁷, CCR⁸R⁸, R²PO, OPOOR², OPO₂, OSO₂, CN, NHNH, NHNR⁶, NR⁶NH, NN, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo or aryl or substituted aryl, and J" is (CR⁷R⁷)n and n=0-3; W is CR⁷R⁷—CR⁷R⁷, CR⁸CR⁸, CR⁷R⁷—CO, NR⁹—CR⁷R⁷, NCR⁸, NN, NR⁹—NR⁹, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, or aryl or substituted aryl; and O, R², R⁶, R⁷, R⁷, R⁸, R⁸, R⁹, R⁹, and R¹⁰ are as defined in the specification, to methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and to pharmaceutical compositions containing such compounds.